Commencing a new series called Pioneers in Health Care, is an interview with Professor Jeremy Chapman AC who for over 30 years, has been involved in nephrectomy, or kidney transplantation.
Honoured “for eminent service to medicine, particularly in the areas of clinical and biomedical research, to the development of ethical policy and practices for organ donation, acquisition and transplantation, and to renal medicine organisations and publications, Jeremy Chapman AC has played significant roles in development of kidney, pancreas and unrelated Bone Marrow Transplantation in Australia.
He has been responsible for global development of ethical transplantation through The Transplantation Society, the World Marrow Donor Association and through advisory roles to the World Health Organisation. He is identified as one of the most influential global leaders in the field of clinical transplantation.
Credit: Australian Academy of Health and Medical Sciences
In September 2022, Western Sydney’s Professor Jeremy Chapman was bestowed the prestigious 2022 Medawar Prize on-stage in Buenos Aires, Argentina.
The Medawar Prize, awarded biennially since 1990 and named after Society co-founder Sir Peter Medawar, is globally recognised as the most prestigious award for excellence in Transplantation Science and Jeremy is “surprised and honoured” saying “not many people get this award so it’s a true delight”.
The award recognises outstanding investigators whose contributions have profoundly influenced organ transplantation.
Professor Chapman has dedicated much of his career to clinical care and research at Westmead, since commencing as a renal physician at Westmead Hospital in 1987. He has worked as Director of Western Renal Services, Westmead Hospital’s Director of Medicine and Cancer, as well as the Director of the Westmead Hospital Foundation, Chair of the Westmead Research Hub Council and member and deputy chair of the board of WSLHD.
In the early days of transplantation long-term care of transplant patients was mostly undertaken by transplant surgeons but as both the numbers and the complexity of transplantation increased, Professor Chapman was amongst the vanguard of renal physicians that focussed, as a physician, on care of patients after their transplant.
“It’s been an interesting road of discovery over time, but also a major transformation in the outcome for our patients,” Professor Chapman said.
“When I was first involved in 1978, we thought a 60% success rate at one year after a transplant was pretty good, even when choosing the very best patients to transplant, now, we would expect more than 90 or 95% success rates in much, much older and sicker patients.”
“Australia has been a great springboard for global activity, so it’s worked out very well to be working in Australia to impact on transplantation globally.”, according to Professor Chapman.
-
Smart wearable technology recognised for improving quality of life
Nurses have a pivotal role to play in the widespread implementation and adoption of digital health technologies throughout the healthcare sector for the primary purpose of improving safety and quality of patient care.
Australian Health Journal talked to two of Australian top leaders in nursing and in digital health on how the role of nursing is pivotal to the success of digital health in the Australian health system.
-
Continuing education program leads to better conversations
Medicines Australia’s Continuing Education Program (CEP) is designed to educate medical representatives to a recognised industry standard. Dr Tristan Ling, CEP Academic Lead and Project Manager at the College of Health and Medicine, University of Tasmania talks about the 900 students that come through the program each year.
The CEP is primarily directed at medical representatives working within the prescription medicines industry, but is also recommended to people who may not be currently employed within the industry but would like to pursue a career as a medical representative. It is also available to personnel working for organisations interacting with the pharmaceutical industry.
-
Child Dental Benefits Schedule needing greater awareness
Since its launch in 2014, the Child Dental Benefits Schedule has seen a gradual increase in participation year on year. The impact of COVID-19 and related shutdowns saw participation fall sharply in 2020. Though it increased 2021, the national target of 41% participation was not reached in 2021-2022, with the total (35.4%) more than three percent below 2018 participation rates.
In an opinion segment, Australian Health Journal spoke with Abano Healthcare Group Clinical Director, Dr Fred Calavassy, with over 30 years of clinical experience, about his observations of the Child Dental Benefits Scheme ways to increasing participation rates.
